Etaracizumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Etaracizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target alpha-v beta-3 integrin
Clinical data
Trade names Abegrin
Identifiers
CAS Number 892553-42-3 N
ATC code none
UNII 41W9MFI160 YesY
KEGG D09342 YesY
Chemical data
Formula C6392H9908N1732O1996S42
Molecular mass 144.3 kg/mol
 NYesY (what is this?)  (verify)

Etaracizumab (also known as etaratuzumab[citation needed], MEDI-522, trade name Abegrin) is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer,[1] ovarian cancer[2] and various other types of cancer.[3] It is manufactured by MedImmune.[1]

Adverse drug effects

Lua error in package.lua at line 80: module 'strict' not found.

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
  1. ↑ 1.0 1.1 Statement On A Nonproprietary Name Adopted By The Usan Council: Etaracizumab
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
Retrieved from "https://infogalactic.com/w/index.php?title=Etaracizumab&oldid=702346135"